The Problem
Pelvic floor disorders such as Urinary Incontinence (UI), Fecal incontinence (FI), and Dyssynergic defecation(DD) affect over 100M in the US alone. Dyssynergic defecation affects 25% of constipation patients (approx. 25M in the US) and is characterized by incoordination of anal and rectal muscles during defecation. Fecal and Urinary Incontinence ( affects 100M-120M in the US) is caused by damage to anorectal muscles and nerves as well as rectal bladder sensation holding capacity
​
Our Mission
Research-based novel therapy
for Pelvic Floor diseases
Normal
Defecation
BioAnatoner introduces
We provide research-based novel solutions to improve pelvic floor disorders such as Constipation and Fecal & Urinary Incontinence. Our solutions are innovative, non-invasive standards of care that are clinically proven and widely prescribed by top Physicians globally. Some of our products include BioAnatoner- for Biofeedback therapy and Digital Apps to digitally monitor these symptoms.
The Solution
Bioanatoner system(BAS) offers a research-based, novel, first-of-its-kind biofeedback therapy solution to improve
all these three (FI,UI, and DD) disorders. BAS provides:
-
Research-based, clinically proven therapy- clinical studies prove improvement of greater than 65% of cases
-
Non-invasive, easy-to-buy and use solution
-
Patients can do this therapy at the convenience of their home or at a healthcare provider’s Office
-
Ability for healthcare providers to remotely monitor progress and provide advice
Dyssynergic
Defecation
The team
Meet our team, our leaders, and problem solvers
Amalesh Sanku
CEO, Co-Founder
Dr. Satish Rao
Co-founder and Advisor
Dr. Ashok Atluri
GI Physician
.jpg)
Mr. David Johnson
Advisor
Ms. Thu-Ha Duncan
Product Developer
Our Clients
Why companies like BioAnatoner?
"Ads performance increased -
Our budget didn't"
I'm a paragraph. Click here to add your own text and edit me. I’m a great place for you to tell a story and let your users know a little more about you.
Sam Whol
Demand Generation lead at ZoZ AI
